Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
1978 1
1980 1
1982 3
1983 1
1984 4
1985 5
1986 6
1987 8
1988 16
1989 4
1990 3
1991 1
1992 5
1993 5
1994 6
1995 5
1996 1
1997 1
1998 1
1999 8
2000 9
2001 10
2002 11
2003 17
2004 11
2005 16
2006 11
2007 23
2008 17
2009 16
2010 24
2011 13
2012 12
2013 27
2014 42
2015 49
2016 49
2017 66
2018 84
2019 89
2020 115
2021 123
2022 118
2023 116
2024 140
2025 137
2026 122

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,362 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: khodakaramiangilan
Page 1
A brief history of NEDA.
Giovannoni G, Bermel R, Phillips T, Rudick R. Giovannoni G, et al. Mult Scler Relat Disord. 2018 Feb;20:228-230. doi: 10.1016/j.msard.2017.07.011. Epub 2017 Jul 13. Mult Scler Relat Disord. 2018. PMID: 29579628 No abstract available.
Are we in need of NEDA?
Freedman MS. Freedman MS. Mult Scler. 2016 Jan;22(1):5-6. doi: 10.1177/1352458515617249. Epub 2015 Nov 9. Mult Scler. 2016. PMID: 26552731 No abstract available.
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.

RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) because of INFL and 10 (8.7%) because of PIRA. ...After a year, NEDA-3 and INFL patients showed similar decreases in sNfL (p < 0.000

…
RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) be …
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. Newsome SD, et al. Neurol Ther. 2023 Dec;12(6):1909-1935. doi: 10.1007/s40120-023-00549-7. Epub 2023 Oct 11. Neurol Ther. 2023. PMID: 37819598 Free PMC article. Review.
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of alternative outcomes and biomarkers, to broaden the clinical information captured by NEDA. ...One such outcome is the set of criteria …
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of a …
NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital.
Bjørnevoll NB, Alstadhaug KB. Bjørnevoll NB, et al. Front Neurol. 2026 Jan 5;16:1698334. doi: 10.3389/fneur.2025.1698334. eCollection 2025. Front Neurol. 2026. PMID: 41561333 Free PMC article.
Compared to patients with evidence of disease activity (EDA), those achieving NEDA-3 after 2 years were older at MS onset (p = 0.046), and a larger proportion were treatment-naive at the start of cladribine (42% vs. 11%, p = 0.03). NEDA-3 was achieved by 36 (60%) pa …
Compared to patients with evidence of disease activity (EDA), those achieving NEDA-3 after 2 years were older at MS onset (p = 0.046) …
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Rotstein D, Solomon JM, Sormani MP, Montalban X, Ye XY, Dababneh D, Muccilli A, Saab G, Shah P. Rotstein D, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Oct 12;9(6):e200032. doi: 10.1212/NXI.0000000000200032. Print 2022 Nov. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36224046 Free PMC article.
However, the ability of NEDA-4 to discriminate long-term outcomes in MS and how its performance compares with NEDA-3 remain uncertain. ...We conducted a meta-analysis using random-effects model to determine the pooled odds ratio (OR) for no disability progression wi …
However, the ability of NEDA-4 to discriminate long-term outcomes in MS and how its performance compares with NEDA-3 remain un …
[Alemtuzumab therapy 2017].
Biernacki T , Bencsik K , Sandi D , Vécsei L . Biernacki T , et al. Ideggyogy Sz. 2017 Nov 30;70(11-12):371-380. doi: 10.18071/isz.70.0371. Ideggyogy Sz. 2017. PMID: 29870645 Free article. Review. Hungarian.
A patient's disease is considered inactive, if it fulfills the criteriae set in the "no evidence of disease activity-3" (NEDA-3) concept, meaning that no progression can be seen on the MRI scans, the patient is relapse free and there is no worsening on any disability scale …
A patient's disease is considered inactive, if it fulfills the criteriae set in the "no evidence of disease activity-3" (NEDA-3) conc …
Posttraumatic growth in eating disorder recovery.
Eaton CM, Phillips KE. Eaton CM, et al. Arch Psychiatr Nurs. 2024 Apr;49:38-46. doi: 10.1016/j.apnu.2024.01.002. Epub 2024 Jan 5. Arch Psychiatr Nurs. 2024. PMID: 38734453
METHODS: The National Eating Disorders Association (NEDA) provided a link to the electronic survey via their website. Participants were asked to complete the Posttraumatic Growth Inventory (PTGI) and the Core Beliefs Inventory (CBI) in the quantitative strand. ...
METHODS: The National Eating Disorders Association (NEDA) provided a link to the electronic survey via their website. Participants we …
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
Di Sabatino E, Gaetani L, Sperandei S, Fiacca A, Guercini G, Parnetti L, Di Filippo M. Di Sabatino E, et al. J Neurol. 2022 Jun;269(6):3129-3135. doi: 10.1007/s00415-021-10901-2. Epub 2021 Nov 24. J Neurol. 2022. PMID: 34820734
METHODS: We included 115 pwMS undergoing treatment with first-line disease-modifying therapies (DMTs) and retrospectively analyzed the presence of NEDA in the whole cohort, either considering or not spinal cord imaging. RESULTS: When considering only clinical and brain MRI …
METHODS: We included 115 pwMS undergoing treatment with first-line disease-modifying therapies (DMTs) and retrospectively analyzed the prese …
Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
Bazzurri V, Fiore A, Curti E, Tsantes E, Franceschini A, Granella F. Bazzurri V, et al. Mult Scler Relat Disord. 2023 Nov;79:105015. doi: 10.1016/j.msard.2023.105015. Epub 2023 Sep 18. Mult Scler Relat Disord. 2023. PMID: 37769430
NEDA-4 meets all NEDA-3 criteria plus lack of brain atrophy. OBJECTIVE: Aim of this study was to investigate the prevalence of two-year NEDA-3, NEDA-4, six-month delayed NEDA-3 (6mdNEDA-3), and six-month delayed NEDA-4 (6mdNEDA-4) in a co …
NEDA-4 meets all NEDA-3 criteria plus lack of brain atrophy. OBJECTIVE: Aim of this study was to investigate the prevalence of …
1,362 results